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Patently Wrong: The U.S. Supreme
Court Punts in the
Case of LabCorp v. Metabolite
John G. New*
ABSTRACT
In June 2006, after having granted certiorari and hearing oral
arguments, the United States Supreme Court dismissed the case of
Laboratory Corp. of America Holdings v. Metabolite Laboratories, Inc.
as having been improvidently granted a writ of certiorari. Dissenting
from this extraordinary step was Justice Breyer, joined by Justices
Stevens and Souter. At issue in the case was a patent, the owners of
which claimed that a physician's use of any test to infer vitamin
deficiency by raised blood serum levels of the chemical homocysteine
infringed the patent. This Article argues that the Supreme Court was
itself improvident in dismissing the case because the patent at issue
claims ownership of a basic scientific fact, a "phenomenon of nature,"
in violation of 35 U.S.C. § 101. Moreover, the lower courts'
construction of the term "correlate" was erroneous in that it was not
determined according to the knowledge of biomedical investigators and
practitioners skilled in that art. Finally, sound public policy
arguments caution against granting such a patent. By failing to act,
the Supreme Court essentially affirmed the U.S. Court of Appeals for
the Federal Circuit's holding that a patent claiming a scientific fact
can be valid, and that practicing physicians who merely think about
that fact are liable for patent infringement.
* J.D., 2007, Chicago-Kent College of Law. Professor of Biology, Loyola
University Chicago; Adjunct Professor of Cell Biology, Neurobiology and Anatomy, Stritch
School of Medicine, Loyola University Chicago. The author gratefully acknowledges the
constructive criticisms of Professor Lori Andrews and Professor Bradley Hulbert.
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In March of 2006, the U.S. Supreme Court heard oral
arguments in the case of Laboratory Corp. of America Holdings v.
Metabolite Laboratories, Inc.1 This case stirred more than the usual
interest that a patent case, even one heard in such an exalted venue,
can generally expect to receive. That interest was manifested by an
unusually large number of amicus briefs submitted to the Court.2 But
on June 22, the Court dismissed the case as having been
improvidently granted a writ of certiorari, which very rarely happens
once oral arguments have been heard. Justice Breyer, joined by
Justices Stevens and Souter, vigorously dissented from the Court's
dismissal of the case. 3
1. 546 U.S. 975, 975 (2005) (per curium) (granting petition for writ of certiorari),
cert. dismissed per curiam, 126 S. Ct. 2921 (2006) (mem.); see Andrew Pollack, U.S. Court
Backs Off Patent Case, INT'L HERALD TRIB., June 24, 2006, at 15.
2. A total of twenty-one amicus briefs were filed by a wide variety of parties,
including the Intellectual Property Owners Association, I.B.M., the Public Patent
Foundation, AARP, and the American Heart Association. See Pollack, supra note 1, at 15;
see, e.g., Brief of American Intellectual Property Law Ass'n as Amicus Curiae Supporting
Respondent, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006)
(No. 04-607) (mem.), 2006 WL 303907; Brief of American Heart Ass'n as Amicus Curiae
Supporting Petitioner, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921
(2006) (No. 04-607) (mem.), 2005 WL 3561169.
3. Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921, 2921
(2006) (No. 04-607) (mem.) (Breyer, J., dissenting).
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The controversy at the heart of this case is the question of how
far the rights protected by a patent may be extended to cover scientific
knowledge. Having tacitly affirmed the decision of the United States
Court of Appeals for the Federal Circuit,4 the Supreme Court has
radically altered the boundaries prohibiting the patenting of
"phenomena of nature." Such a decision will likely have negative and
far-ranging consequences for the practice of medicine, essentially
rendering the mental processes forming the basis of a diagnostic
decision patentable and subject to licensing fees. Such patents will act
to the detriment of the practice of medicine in this country at the level
of doctor-patient interactions, as well as on the development and
advancement of medical research.
Specifically, the language of claim 13 of the patent in dispute,
U.S. Patent No. 4,940,658 (the '658 patent), claims in part the
correlation of elevated levels of the amino acid homocysteine with
decreased levels of folic acid (folate) and vitamin B 12 (also known as
cobalamin). 5 The language of the claim also embraces any assay
6
used to detect homocysteine, including those anticipated in the prior
art and those not yet developed, if it is used to infer folate or vitamin
B,2 deficiency in a patient.7 In 2001, the U.S. District Court for the
District of Colorado held that this patent was indirectly infringed
8
when Laboratory Corporation of America Holdings (LabCorp), a
medical testing laboratory, employed a noninfringing homocysteine
assay that allowed physicians to diagnose vitamin deficiency in
patients with elevated homocysteine levels.9
Metabolite Laboratories, Inc. (Metabolite), the holder of the
'658 patent, argued successfully that any homocysteine-only test that
permitted physicians to make such an inference between the levels of
homocysteine and vitamin deficiency infringed its patent.'0 Moreover,
Metabolite also argued successfully that any publication that
4. See generally Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d
1354 (Fed. Cir. 2004) (affirming a finding of willful infringement of a patent claiming a
method for detecting vitamin deficiencies).
5. U.S. Patent No. 4,940,658 col.41 11.58-65 (filed Nov. 20, 1986).
6. An "assay" is a "laboratory test performed to measure the activity of a
substance against a certain target" and "must maintain a certain minimal level of
biological activity to be considered for animal or clinical testing." LARRY L. MAI ET AL., THE
CAMBRIDGE DICTIONARY OF HUMAN BIOLOGY AND EVOLUTION 41 (2005).
7. '658 Patent col.6 11.1-4.
8. Metabolite Labs., Inc., 370 F.3d at 1358; see Metabolite Labs., Inc. v. Lab. Corp.
of Am. Holdings, No. 99-CV-870, 2001 WL 34778749, at *1 (D. Colo. Dec. 3, 2001).
9. Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1365 (Fed.
Cir. 2004).
10. See id. at 1371-72.
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described the relationship between homocysteine levels and vitamin
deficiency could be viewed by the courts as an inducement to
infringe.11 Thus, the holders of the '658 patent claim nothing less
than the mental process of inferring the relationship between elevated
homocysteine levels in the body and decreased levels of folate and
vitamin B12. The district court's finding of indirect infringement was
subsequently upheld on appeal by the U.S. Court of Appeals for the
Federal Circuit.
12
This Article will examine the history of the Metabolite case as
well as the arguments made before the Court. Part I will explain the
scientific principles underlying the patent in dispute and their
relationship to the prior art. Part II will follow the history of the
Metabolite case in the lower courts and review the arguments made to
the Supreme Court in Petitioner's and Respondent's briefs. Part III
will argue that, rather than dismiss the case, the Court should have
vacated the decision of the U.S. Court of Appeals for the Federal
Circuit and held claim 13 of the '658 patent invalid. First, this part
will demonstrate that the Federal Circuit relied upon an erroneous
construction of the claim language by the district court in its
Markman hearing, specifically with respect to the construction of the
word "correlate."1 3 Second, this part will contend, as argued by
Justice Breyer's dissent, that the Court could have properly
considered the patentability of the subject matter of claim 13 under
the Constitution and under 35 U.S.C. § 101. Third, this part will
contend that the language of the disputed claim 13 is so overly broad
as to render it invalid under 35 U.S.C. § 102. Finally, this part will
discuss the potentially catastrophic implications for the practice of
medicine in this country following the Supreme Court's failure to
overturn the Federal Circuit's decision.
I. THE SCIENCE AND THE '658 PATENT
The Metabolite case involves the use of an assay for the amino
acid homocysteine as an indicator of potentially deleterious vitamin
deficiency in the human body. It may therefore be useful to the reader
to briefly review some of the biological concepts that form the basis of
the '658 patent and lie at the heart of the dispute in this case.
11. See id. at 1365 ("[A] reasonable jury could find intent to induce infringement
because LabCorp's articles state that elevated total homocysteine correlates to
cobalamin/folate deficiency.").
12. Id. at 1358.
13. See id. at 1361-64 (reviewing and affirming the district court's construction of
"correlate" to mean "establish[ing] a mutual or reciprocal relationship between").
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Proteins form an important constituent of the chemical
makeup of the human body. They may act as structural elements of
body tissues, elements in the body's defense mechanisms, chemical
signals between various cells in the body, transport elements moving
compounds in and out of cells, and as enzymes that catalyze the
chemical reactions forming the basis of metabolism. 14 Proteins consist
of one or more long, folded chains of chemicals known as amino
acids.15 There are over 300 naturally occurring amino acids present in
biological systems; however, only twenty amino acids form all of the
proteins found in the body. 16 Chemical interactions resulting in the
formation of chemical bonds between the amino acids forming the long
polypeptide chains give a protein its distinctive three-dimensional
configuration. 17 Such a configuration is essential to the function of
proteins; when the bonds formed by the interactions of amino acids
are disrupted, the protein's configuration breaks down (denatures)
and loses its functional capacity.' 8 Of the twenty amino acids used in
the synthesis of proteins, eight must be obtained from the diet (the
essential amino acids); the remainder can be synthesized in the body
from precursor organic molecules. 19
Vitamins are organic molecules that are vital to the health of
the individual, but which are required in only minute amounts.20
Although they have a variety of functions, one of the most important is
to act as coenzymes in concert with protein enzymes to catalyze
important metabolic chemical reactions. 2' Two water-soluble
vitamins, folate and B12, are of relevance to the Metabolite case. Both
14. DAVID L. NELSON & MICHAEL M. Cox, LEHNINGER PRINCIPLES OF
BIOCHEMISTRY 113-14 (3d ed. 2000). Catalysis by enzymes lowers the energy of activation
(Ea) of chemical reactions, accelerating the rate at which chemical reactions proceed from
reactant to product. Id. at 248.
15. See generally id. at 152-53 (summarizing the structures of various proteins).
Amino acids are so called because they possess at least one basic amino group (-NH3) and
one carboxylic acid group (-COOH) attached to a variable group (R), which gives the amino
acid its identity. Id. Condensation reactions between amino and carboxyl groups of amino
acids result in the formation of a highly stable covalent peptide bond, enabling the
formation of chains of amino acids of considerable length. Id. at 116. Condensation
reactions between amino and carboxyl groups of amino acids result in the formation of a
highly-stable covalent peptide bond, enabling the formation of chains of amino acids of
considerable length. Id. at 126.
16. ROGER K. MURRAY ET AL., HARPER'S ILLUSTRATED BIOCHEMISTRY 14 (26th ed.
2003).
17. See NELSON & COX, supra note 14, at 199.
18. Id.
19. See MURRAY ET AL., supra note 16, at 237.
20. NELSON & COX, supra note 14, at app. G-14.
21. Id.
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of these vitamins act as coenzymes in the synthesis of amino acids and
nucleic acids. 22 Deficiencies of folate and B12 can result in a number of
serious health problems, including anemia, cardiovascular disease,
neural tube-related birth defects such as spina bifida, and possibly
neuropsychiatric disorders.
23
Homocysteine is an amino acid occurring in the human body,
but it is not one of the twenty amino acids employed in the structure
of proteins. 24 Rather, it is an intermediate compound in the synthesis
of several of those amino acids occurring in proteins. 25 Although a
detailed discussion of the biochemical interactions between folate, B 12,
and homocysteine is beyond the scope of this paper, both folate and
B 1 2 are essential cofactors in the conversion of homocysteine to
methionine, one of the amino acids used in proteins, and is itself
important in the synthesis of other amino acids.
26
The roles of folate and B12 in the synthesis of methionine have
been well known for over thirty years. Although the precise
mechanisms of how they cause the symptoms presented in cases of
folate- or B12-deficiencies are less clear, the metabolic pathways
employing folate and B 1 2 in the conversion of homocysteine to the
amino acid methionine were well understood long before the '658
patent was filed in 1985.27 Furthermore, elevated homocysteine levels
were demonstrated to induce arteriosclerosis in primates prior to the
application date of the '658 patent; studies of this sort relied in part on
22. See MURRAY ET AL., supra note 16, at 51.
23. See id. at 492, 494; NELSON & COX, supra note 14, at 611.
24. N.V. BHAGAVAN, MEDICAL BIOCHEMISTRY 354 (4th ed. 2002).
25. See id. at 354-55.
26. Id. at 355. Briefly, both B 12 and folate (in its active form, tetrahydrofolate) are
important in the synthesis of the amino acid methionine. NELSON & COX, supra note 14, at
642. Homocysteine acts as methyl group donor, forming methionine from 5-methyl-
tetrahydrofolate via the activity of the enzyme 5-methyl-tetrahydrofolate-homocysteine
transferase. Id. at 831. Methylcobalimin, a form of vitamin B 12, also plays an important
intermediate role in the methylation of 5-methyl-tetrahydrofolate by homocysteine to form
methionine. Id. at 642. Methionine in turn plays a vital metabolic role as a methyl group
donor to a number of other biologically important compounds, including creatine,
phosphatidylcholine, epinephrine, cyclic fatty acids, and others. COLLEEN SMITH ET AL.,
MARK'S BASIC MEDICAL BIOCHEMISTRY: A CLINICAL APPROACH 732 (2d ed. 2005). However,
methionine can only be synthesized via the limited reactions described above; thus,
methionine synthesis via homocysteine forms a metabolic "choke point" in the formation of
a number of important compounds. See id. ("This is the only reaction in which methyl-
tetrahydrofolate can donate the methyl group. If ... B12 or [folate] levels are insufficient,
homocysteine will accumulate.").
27. See, e.g., Jeffrey M. Gawthorne & Richard M. Smith, Folic Acid Metabolism in
Vitamin B12-Deficient Sheep: Effects of Injected Methionine on Methotrexate Transport and
the Activity of Enzymes Associated with Folate Metabolism in Liver, 142 BIOCHEMISTRY J.
119, 125 (1974) (Gr. Brit.) (concluding that a B12 deficiency resulted in an impaired
transformation of homocysteine to methionine).
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well-established assays of serum homocysteine levels. 28 However, the
relationship between elevated homocysteine levels in body fluids and
tissues and the etiology of diseases associated with folate and B12
deficiency are complex and still not entirely understood. 29
The '658 patent, entitled Assay for sulfhydryl amino acids and
methods for detecting and distinguishing cobalamin and folic acid
deficiency, was filed with the U.S. Patent Office on November 20,
1986.30 In general, the patent claims a method for determining levels
of homocysteine in samples of body fluids from warm-blooded animals.
Specifically, the patent claims a method for detecting vitamin B12
(cobalamin) and folate deficiencies that employ a specific assay for
total homocysteine levels, and a method for distinguishing deficiencies
of B 12 from folate using an assay for total homocysteine in combination
with an assay for methylmalonic acid.31 The inventors named in the
patent, Robert H. Allen, Sally P. Stabler, and John Lindenbaum,
assigned the patent rights to University Patents, Inc. (UPI) of
Westport, Connecticut. 32 The U.S. Patent and Trademarks Office
granted the patent on July 10, 1990. 33
On its face, much of the '658 patent is an unobjectionable
method patent describing an assay for total homocysteine levels in
animal tissue. It satisfies the established requirements of novelty,
utility, and nonobviousness, 34 and it also fulfills the enablement,
written description, and best mode requirements of 35 U.S.C. § 112. 35
However, claim 13 stands out as something different-the eye of the
28. See, e.g., Laurence A. Harker et al., Homocysteine-Induced Arteriosclerosis: The
Role of Endothelial Cell Injury and Platelet Response in its Genesis, 58 J. CLINICAL
INVESTIGATION 731, 733 (1976) (citing Darrel H. Spackman et al., Automatic Recording
Apparatus for Use in the Chromatography of Amino Acids, 30 ANALYTICAL CHEMISTRY
1190, 1190-99 (1958)) (quantifying homocysteine by "column chromatography using a
modified procedure of Spackman et al.").
29. See COUNCIL ON SCIENTIFIC AFFAIRS, AM. MED. ASS'N, FOLIC ACID
RELATIONSHIPS TO SPINAL CLOSURE BIRTH DEFECTS AND ADULT VASCULAR DISEASE
(1995), available at http://www.ama-assn.org/ama/pub/category/13679.html (recommending
increased funding for "basic research, epidemiologic studies, and clinical trials to assess
expeditiously the ... metabolic interrelationships of folate, vitamin B6 and vitamin B12").
30. U.S. Patent No. 4,940,658 at 22 (filed Nov. 20, 1986).
31. Id. at [57]. "[T]otal homocysteine" includes homocysteine in "both free and
complexed forms." Id. col.7 11.26-29.
32. Id. at [75], [73].
33. Id. at [45].
34. See 35 U.S.C. §§ 101-03 (2000 & Supp. 2003-2004).
35. See id. § 112 (2000).
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storm swirling about the Metabolite case. 36 Claim 13 claims in its
entirety:
A method for detecting a deficiency of cobalamin or folate in warm-blooded animals
comprising the steps of: assaying a body fluid for an elevated level of homocysteine;
and correlating an elevated level of total homocysteine in said body fluid with a
deficiency of cobalamin or folate.
37
In short, claim 13 claims the use of any method for measuring
homocysteine levels (not just those covered in the patent's other
claims) and the use of those results to infer cobalamin or folate
deficiencies from elevated levels of homocysteine.
UPI's successor to the rights to the '658 patent, Competitive
Technologies, Inc., licensed the patent to Metabolite, which in turn
sublicensed the patent to Roche Biomedical Laboratories (later
LabCorp). LabCorp performed the homocysteine assays under the
license. 38  However, in 1998, LabCorp abandoned the total
homocysteine assay licensed from Metabolite in favor of one developed
by Abbott Laboratories. 39  Consequently, LabCorp ceased paying
royalties to Metabolite when it discontinued use of the '658 patent
assay.40 Metabolite brought suit against LabCorp in the U.S. District
Court for the District of Colorado alleging breach of contract, patent
infringement, and contributory infringement of the '658 patent. 41
II. METABOLITE: THE LITIGATION HISTORY
A. The Decisions in the District and Federal Circuit Courts
Metabolite Laboratories, Inc. v. Laboratory Corp. of America
Holdings went to trial before a jury and Judge Zita L. Weinshienk on
November 5, 2001.42 On November 20, 2001, the jury returned a
verdict against LabCorp, awarding Metabolite over three million
dollars in damages for breach of contract and an additional one million
36. See Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1361
(Fed. Cir. 2004).
37. '658 Patent col.41 11.58-65.
38. Metabolite Labs., Inc., 370 F.3d at 1359.
39. Id.
40. Id.
41. Second Amended Complaint and Jury Demand at 90-94, 107-14, Metabolite
Labs., Inc. v. Lab. Corp. of Am. Holdings, No. 99-CV-870, 2001 WL 34778749 (D. Colo. Jan.
31, 2000).
42. Metabolite Labs. Inc. v. Lab. Corp. of Am. Holdings, No. 99-CV-870, 2001 WL
34778749, at *1 (D. Colo. Jan. 31, 2000).
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dollars for the indirect infringement counts. 43  After denying
LabCorp's motion for judgment as a matter of law, the district court
doubled the infringement award, finding that LabCorp willfully
infringed the '658 patent, and issued a permanent injunction against
LabCorp, preventing it from using the homocysteine-only test.44
LabCorp appealed to the U.S. Court of Appeals for the Federal
Circuit, arguing that the district court erred in denying its motion for
judgment as a matter of law. 45 Specifically, LabCorp disputed the
district court's construction of the term "correlating" in the second
part of claim 13.46 It was upon the construction of this term that the
finding of direct and indirect infringement by the jury hinged.47
Reviewing the construction of the claim de novo, the court of
appeals properly asserted that it would discern the language of the
claim-including the term "correlating"-in the context of the
"understanding of [such] terms among artisans of ordinary skill in the
relevant art at the time of invention."48 The court noted that intrinsic
evidence (the usage of terminology in the patent claims, specifications,
and prosecution history) as well as extrinsic evidence (expert
testimony, treatises, dictionaries, etc.) could be used in construing the
language of the patent claims and the terminology contained therein. 49
In determining the level of ordinary skill in the art, through which the
claims should be construed, the court adopted the district court's
standard: '[A] person having a medical degree and experience in
researching the amino acid homocysteine and its relationship to
diseases."'
50
In reviewing the district court's Markman 1 hearing for its
construction of the term "correlating," as well as the prosecution
history,52  the court of appeals affirmed the district court's
43. Id.
44. Metabolite Labs. Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1359 (Fed.
Cir. 2004).
45. Id.
46. See id. at 1361.
47. See id. at 1360.
48. Id. at 1360 (citing Rexnord Corp. v. Laitram Corp., 274 F.3d 1336, 1342 (Fed.
Cir. 2001)).
49. Id.
50. Id. at 1361 (quoting the jury instructions at the district court level).
51. Markman v. Westview Instruments, Inc., 517 U.S. 370, 372 (1996) (holding that
claim construction is a matter of law and that "the construction of a patent, including
terms of art within its claim, is exclusively within the province of the court").
52. See Metabolite Labs., Inc., 370 F.3d at 1362. As originally filed, claim 13 lacked
the "correlating" step and was rejected by the examiner for failure to comply with 35 U.S.C.
§ 112 in providing a complete written description of the sequential steps of the process. Id.
The rejection was later withdrawn, but the claim was again rejected under 35 U.S.C. § 102
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interpretation. 53  According to the court of appeals, "correlating"
should be construed to mean "relating total homocysteine levels to
cobalamin or folate deficiency, a deficiency in both, or a deficiency in
neither."54 Correlating, as thus defined by the circuit court, "includes
both a mutual relationship between the presence of an elevated level
of homocysteine and a vitamin deficiency and a reciprocal relationship
between the absence of an elevated level of homocysteine and no
vitamin deficiency." 55 Furthermore, according to the court of appeals,
the claim language required no "confirmatory step" linking either
condition to diagnosed or apparent symptoms.
56
The court of appeals then addressed LabCorp's challenge to the
validity of claim 13 of the '658 patent.57 LabCorp argued that the
claim was invalid because of its indefiniteness, as well as its failure to
meet 35 U.S.C. § 112's requirements of a written description and
enablement. 5  The court affirmed the district court's Markman
finding that there were "no 'material ambiguities' cloud[ing] the
meaning of the term 'correlating' to the extent that one of skill in the
art would find the claim wholly indefinite," and thus, invalid.
59
Likewise, the court held that the jury's finding that physicians
engaged in homocysteine research, who were persons of ordinary skill
in the art, "understood from the specification that the '658 patent
inventors possessed the 'correlating' step at the time they filed the
patent application," was supported by substantial evidence. 60 Finally,
the court of appeals held that the language of the claim itself enabled
"one of ordinary skill in the art" to practice the method described in
the claim.61 According to the court, "[t]he correlating step is a simple
conclusion that a cobalamin/folate deficiency exists vel non based on
the assaying step," and it noted that the correlation was neither
concealed nor undisclosed, but was the "centerpiece of the invention."62
Next, the court of appeals rejected LabCorp's argument that
claim 13 was obvious and therefore, invalid under 35 U.S.C. §§ 102 or
as merely citing an intended use. Id. The "correlating" language was then added to
overcome this latter rejection. Id.
53. Id. at 1363-64.
54. Id. at 1363.
55. Id. at 1364.
56. Id.
57. See id. at 1365-68.
58. Id. at 1366; see 35 U.S.C. § 112 (2000).
59. Metabolite Labs., Inc., 370 F.3d at 1366.
60. Id.
61. See id. at 1366-67.
62. Id. at 1367.
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103.63 The court noted that, although the prior art reference, an
article by Professor Helga Refsum, 64  did disclose that total
homocysteine should be used to investigate 'perturbations of
homocysteine metabolism in humans during disease [sic] or
pharmacological interventions that affect metabolism of one-carbon
compounds,"' the reference did not specifically mention cobalamin or
folate deficiencies but merely "invite[d] further experimentation to
find such associations." 65 The court held that LabCorp failed to meet
its heavy burden of proof of demonstrating that the prior art disclosed
enough evidence to show that a person "in the art would have been
motivated to combine the various references"; the disputed claim was
therefore nonobvious.6
6
Having thus concluded that, under claim 13, any test for
homocysteine could be used to infer decreased levels of folate andlor
cobalamin, the court found that substantial evidence supported the
jury's verdict of indirect infringement. 67 Dr. Peter Wentz, a LabCorp
Director, testified at trial that "'the correlating step ... [is] a separate,
distinct step that's performed by the physician who receives . . .our
results."'68 Dr. Sally Stabler, one of the inventors of the '658 patent,
also testified that "it would be malpractice for a doctor to receive [the
results of] a total homocysteine assay without determining
cobalamin/folate deficiency."69
In its finding, the court of appeals extended the definition of
"correlating" to mean that any physician who made the logical
inference that an assay revealing elevated levels of total homocysteine
in a patient and also predictively indicating low levels of folate and/or
cobalamin was infringing upon claim 13 of the '658 patent.70 The
63. See id. at 1367-68. The court noted that a prior art reference anticipates a
patent claim under § 102 'if the reference discloses, either expressly or inherently, all of
the limitations of the claim."' Id. at 1367 (quoting EMI Group N. Am., Inc. v. Cypress
Semiconductor Corp., 268 F.3d 1342, 1350 (Fed. Cir. 2001)).
64. See Helga Refsum et al., Radioenzymic Determination of Homocysteine in
Plasma and Urine, 31 CLINICAL CHEMISTRY 624 (1985).
65. Metabolite Labs., Inc., 370 F.3d at 1367 (quoting Helga Refsum et al.,
Radioenzymic Determination of Homocysteine in Plasma and Urine. 31 CLINICAL
CHEMISTRY 624 (1985) ("[P]erturbations of homocysteine metabolism in humans during
diseases or pharmacological interventions that affect metabolism of one-carbon
compounds.")).
66. Id. at 1368 (citing Ecolochem, Inc. v. S. Cal. Edison Co., 227 F.3d 1361, 1372
(Fed. Cir. 2000)).
67. See id. at 1365.
68. Id. at 1364 (alteration in original).
69. Id. at 1364.
70. See id. at 1364-65. Since homocysteine is a precursor of methionine and folate
and B, 2 are essential to its conversion, deficiencies of folate and B12 will result in an
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circuit court also found that, by publishing literature describing the
relationship between elevated homocysteine levels and vitamin
deficiency and by offering to perform homocysteine assays with
Abbott's non-infringing method, LabCorp had actively induced
physicians to infringe upon the '658 patent by encouraging them to
diagnose a vitamin deficiency based upon increased total
homocysteine levels. 71
LabCorp appealed the Federal Circuit's decision. After a
rehearing en banc was denied by the Federal Circuit,72 an appeal to
the Supreme Court was granted certiorari on October 31, 2005.73
Certiorari was limited to Question 3 of Petitioner's brief:
Whether a method patent setting forth an indefinite, undescribed, and non-
enabling step directing a party simply to "correlat[e]" test results can validly claim
a monopoly over a basic scientific relationship used in medical treatment such that
any doctor necessarily infringes the patent merely by thinking about the
relationship after looking at a test result.
7 4
The question of whether a patent could claim even the pondering of a
basic scientific relationship would thus be considered by the Supreme
Court.
B. The Arguments on Appeal to the Supreme Court
In its petition for certiorari, LabCorp pointed out that the
Federal Circuit's opinion posed grave dangers for the practice of
medicine. If the Federal Circuit's affirmation of the construction of
"correlating" was upheld by the Court, then
any person-such as an author of a medical textbook-would be guilty of induced
infringement if he or she simply published the basic scientific fact that elevated
levels of homocysteine correlate to deficiencies of cobalamin or folate. . . . A
truthful statement of medical fact-standing alone-cannot under any
circumstances constitute a specific intent to infringe a patent.
7 5
increase in homocysteine levels since the action cannot "go forward." See SMITH ET AL.,
supra note 26, at 732.
71. Metabolite Labs., Inc., 370 F.3d at 1365. The circuit court vacated the district
court's finding of infringement of another claim in the '658 patent for lack of subject matter
jurisdiction, affirmed the jury's finding of breach of contract, and held that the district
court did not abuse its discretion in both awarding enhanced damages to Metabolite and
issuing the injunction against LabCorp. Id. at 1369-72.
72. See Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, No. 03-1120, 2004 U.S.
App. LEXIS 17408, at *1 (Fed. Cir. Aug. 5, 2004).
73. Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 546 U.S. 975, 975 (2005)
(per curium).
74. Petition for Writ of Certiorari at i, Lab. Corp. of Am. Holdings v. Metabolite
Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-607) (mem.), 2004 WL 2505526.
75. Id. at 18.
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Furthermore, LabCorp argued that "[tjo hold otherwise would
dramatically transform the patent laws from an engine of discovery
into a means of preventing the dissemination of basic scientific
information,"76 and pointed out the Court's longstanding recognition
that "laws of nature are outside the scope of patentable inventions."77
LabCorp argued that the Federal Circuit improperly construed
the '658 patent as conferring a monopoly on the mental processes of
doctors. 78 By holding that a physician directly infringes merely by
"look[ing] at a homocysteine test result and think[ing] about a possible
connection to vitamin deficiencies," without reference to what type of
assay is employed or to whether further confirmatory tests are
required, LabCorp claimed that the Federal Circuit improperly
broadened the scope of patent law. 79 Furthermore, LabCorp argued
that the Federal Circuit erred in holding that a third-party such as
LabCorp, which did not infringe directly by employing the non-
infringing Abbott homocysteine assay, could be held liable for inducing
infringement by physicians.8 0 According to LabCorp's argument, since
no person can patent a scientific fact or principle, it follows that "no
person can be guilty of induced infringement merely by stating such a
fact" in a publication or by offering to perform a noninfringing test
that demonstrates that fact.81
LabCorp argued further that the disputed claim 13 was
"[i]ndefinite, [i]nsufficiently [d]escribed, [a]nd [n]on-[e]nabling."8 2
LabCorp argued that because it embraces all assays for homocysteine,
including those claimed in the patent, those described in the prior art,
and even those not yet developed, and because it does not describe the
method by which an individual is to "correlate" an elevated
homocysteine level with a vitamin deficiency, the claim attempts to
assert a patent monopoly over a scientific fact and is therefore
invalid.8 3 A claim that simply directs a practitioner to correlate a test
result with a medical condition fails to meet the requisite standard of
76. Id.
77. Id. (citing Diamond v. Diehr, 450 U.S. 175, 185 (1981); Gottschalk v. Benson,
409 U.S. 63, 67 (1972); Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948);
Mackay Radio & Tel. Co. v. Radio Corp. of Am., 306 U.S. 86, 94 (1939)).




82. Id. at 23.
83. See id.
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"accuracy, precision, and care" in disclosing the invention.8 4 Moreover,
LabCorp asserted that claim 13 fails to
contain a written description of the invention, and of the manner and process of
making and using it, in such full, clear, concise, and exact terms as to enable any
person skilled in the art to which it pertains, or with which it is most nearly
connected, to make and use the same.
85
LabCorp argued that the term "correlate" is impermissibly vague
because it fails to set forth any correlating step beyond merely
thinking about a simple scientific fact-the relationship between
elevated homocysteine levels and vitamin deficiency.8 6 Therefore, a
physician of ordinary skill in the art "cannot determine [the claim's]
scope without speculation. 87 For the same reasons, LabCorp argued,
claim 13 must also fail the written description and enablement
requirements of 35 U.S.C. § 112.88
According to LabCorp, the correlating step as construed by the
lower court would not require a doctor to actively perform any discrete
step in the patented process, but merely to possess the knowledge of
the link between elevated homocysteine levels and cobalamin and
folate deficiencies. Thus, anyone might obtain a patent on a scientific
correlation such as a link between two sets of facts "merely by drafting
a patent claiming no more than 'test for fact A and correlate with fact
B,' without any explanation of the testing or correlation processes."
8 9
Such a construction of an undefined claim cannot constitute a valid
patented invention because it merely states a scientific fact and does
not define any novel invention.90
Finally, LabCorp argued in its brief that there are important
policy reasons for overturning the holding of the Federal Circuit.91
LabCorp maintained that, although a patent may properly protect a
test for obtaining information, patent law "cannot, and should not,
84. See Brief for Petitioner at 34, Lab. Corp. of Am. Holdings v. Metabolite Labs.,
Inc., 126 S. Ct. 2921 (2006) (No. 04-607) (mem.), 2005 WL 3543099 (quoting Merrill v.
Yeomans, 94 U.S. 568, 573 (1876)).
85. Petition for Writ of Certiorari, supra note 74, at 24 (quoting 35 U.S.C. § 112
(2000)).
86. See id.
87. Id. at 24-25.
88. See id. at 25; 35 U.S.C. § 112 ("The specification shall contain a written
description of the invention, and of the manner and process of making and using it, in such
full, clear, concise, and exact terms as to enable any person skilled in the art to which it
pertains, or with which it is most nearly connected, to make and use the same, and shall
set forth the best mode contemplated by the inventor of carrying out his invention.").
89. Brief for Petitioner, supra note 84, at 14.
90. See id.
91. See Petition for Writ of Certiorari, supra note 74, at 26-27.
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protect the medical facts that a test result [or assay] may convey."92
Such protection may prevent medical professionals from exercising
sound professional judgment if the "threat of patent lawsuits pressure
doctors to delay or refrain from learning about medical facts that could
help provide appropriate care and diagnosis."93 By holding that a
doctor's merely thinking about the relationship between a detected
elevation in homocysteine in a patient as an indicator of vitamin
deficiency is a direct infringement of the '658 patent, LabCorp argued
that the Federal Circuit cast a "pall" over the very nature of patient
care.
94
Furthermore, LabCorp alleged that, should the Supreme Court
find claim 13 of the '658 patent valid, then any "test plus correlate"
patent would likewise be similarly valid.95 Such a patent could
directly inhibit the free dissemination of scientific information
between medical and scientific investigators that is at the very heart
of biomedical and scientific research.96 LabCorp warned that the
Federal Circuit's decision would have disastrous consequences for
medical care and research in the United States.
97
In its reply brief, Metabolite attacked LabCorp's arguments at
statutory, procedural, and policy levels.98 First, Metabolite argued
that subject matter patentability was not properly brought before the
Court.99 According to Metabolite, LabCorp's argument that claim 13
attempted to patent a basic scientific fact or phenomenon of nature in
violation of 35 U.S.C. § 101 was never argued or invoked in the courts
below, and was only raised in Petitioner's Brief to the Court.100
Metabolite quoted the Patent Act of 1952, which states that invalidity
of the patent on any ground-including the § 101 ban on patenting
phenomena of nature-"'shall be defenses in any action involving the
validity or infringement of a patent and shall be pleaded."' 01
According to Metabolite, because LabCorp's underlying suit attacked
the '658 patent only on grounds of lack of novelty (§ 102), obviousness
92. Id. at 27.
93. Id.
94. Id.
95. Id. at 29.
96. See id. at 28-29.
97. See id. at 27.
98. See Brief for Respondents, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc.,
126 S. Ct. 2921 (2006) (No. 04-607) (mem.), 2006 WL 303905.
99. Id. at 19.
100. See id. at 19 ("[W]ith the exception of a single cryptic footnote in its merits brief
filed in this Court, petitioner has never so much as cited, much less invoked or discussed,
Section 101 in the long history of [the] litigation." (internal citation omitted)).
101. Id. at 21 (quoting 35 U.S.C. § 282 (2000)).
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(§ 103), and indefiniteness (§ 112),' 02 LabCorp was now barred from
making an attack not pleaded in the lower courts or submitted to a
jury on the grounds of patentability based upon § 101.103
Moreover, Metabolite contended that LabCorp's attempt to
attack the '658 patent on § 101 grounds also offended the Federal
Rules of Civil Procedure. 104 By failing to plead an infringement
defense based on § 101 in the lower courts, Metabolite claimed that
LabCorp violated Federal Rule of Civil Procedure 8(c), which requires
defendants to plead 'any . . .matter constituting an avoidance or
affirmative defense. '"' 10 5  Furthermore, Metabolite argued that
LabCorp's failure to raise the issue at all until the case reached the
merits stage at the Supreme Court should also act as a bar against
employing the defense now. 10 6 In essence, Metabolite's "use it or lose
it" argument sought to bar the Court from even considering LabCorp's
arguments concerning § 101 invalidity, and to restrict the Court to
considering only LabCorp's defenses based on §§ 102, 103, and 112.107
Although LabCorp argued that the issue was "fairly included in
Question 3" of the Grant of Certiorari issued by the Court,108
Metabolite argued that the Court's own rules prevented
consideration. 10 9 According to Metabolite, the sole issue before the
Court was the review of the lower court's decision that claim 13 of the
'658 patent met the written description and enablement requirements
of 35 U.S.C. § 112.110 Metabolite maintained that, since the Court did
not grant certiorari on the question of whether LabCorp could be held
liable for infringing the '658 patent merely for disseminating a
scientific fact (the relationship between elevated homocysteine levels
and vitamin deficiency), an attack by LabCorp on § 101 grounds was
prohibited."'
102. Id.
103. Id. at 22 (citing Elec. Storage Battery Co. v. Shimadzu, 307 U.S. 5, 16-17 (1939);
Johnson & Johnson v. C. B. Stenvall, Inc., 193 F. Supp. 128, 132 (S.D.N.Y. 1961)).
104. See id.
105. Id. (quoting FED. R. CIV. P. 8(c)) (alteration in original).
106. Id. at 23 (citing Helvering v. Tex-Penn Oil, Co., 300 U.S. 481, 497-98 (1937)
(barring defendant from seeking a ruling on an issue that it had not sought in a lower
court)).
107. See id. at 25.
108. Brief for Petitioner, supra note 84, at 17 n.9.
109. Brief for Respondents, supra note 98, at 25.
110. See id. at 26.
111. See id.
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Metabolite maintained that claim 13 of the '658 patent claimed
patentable subject matter. 112 Metabolite contended that the disputed
claim did employ a scientific fact that could be determined using the
assay that the patent described. 113  Metabolite argued that the
technical application (the homocysteine assay) employed a law of
nature, but that useful inventions employing such natural laws fall
within the realm of patentable subject matter.114 Metabolite cited, in
support of its contention, Diamond v. Diehr, in which the Supreme
Court held that a "mathematical equation or a law of nature. . ., when
incorporated as part of a process that yields a more efficient or useful
end, '... is at the very least not barred at the threshold by § 101."'
1 5
Metabolite also argued that claim 13 met the requirements of §
101 because the assay in question entails a physical transformation of
matter." 6 Metabolite dismissed LabCorp's argument that the assay
was in no way transformative, but merely measures the homocysteine
level present." 7 According to Metabolite, the chemical transformation
steps required as a part of the assay in order to provide a detectable
measure of homocysteine satisfied the transformative requirement."
8
Thus, the chemical reactions required to assay homocysteine satisfied
the transformative element required to validate the patent." 9
Moreover, Metabolite championed the validity of the '658
patent because the correlation, when combined with an assay, is
instrumental in producing a "useful, tangible, and concrete result."' 2°
The patent, argued Metabolite, is clearly useful in that it detects
potentially dangerous vitamin deficiencies in patients-deficiencies
that can lead to a number of potentially life-threatening health
112. Id. at 27 (assuming arguendo that the issue of § 101 patentability was even
before the Court).
113. See id. at 29.
114. See id. at 32 ("[A] natural phenomenon 'in the abstract' does not constitute
patentable subject matter, but a claimed invention does meet Section 101's subject matter
requirements when the phenomenon 'has been reduced to some practical application
rendering it useful."' (citations omitted) (internal quotation marks omitted)).
115. Id. (quoting Diamond v. Diehr, 450 U.S. 175, 188 (1981)).
116. See id. at 34 ("Because the invention of claim 13 requires the transformation of
matter (i.e., blood or other body fluid) in order to diagnose vitamin deficiencies, it is
patentable under Section 101.").
117. See id.
118. See id.; see also U.S. Patent No. 4,940,658 col.7 11.12-14 (filed Nov. 20, 1986)
("Reduction is required for release and subsequent assay of protein bound sulfhydryl
compounds.").
119. Brief for Respondents, supra note 98, at 35.
120. Id. at 36 (citing State St. Bank & Trust Co. v. Signature Fin. Group, Inc., 149
F.3d 1368, 1373, 1375 (Fed. Cir. 1998)).
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consequences. 12 1 The results of the method described by the patent
are likewise tangible, according to Metabolite, in that the assay
provides measurable results that may accurately predict a
corresponding deficiency. 122 And because the results of the test are
repeatable and predictable, they are "concrete," as defined by the
Patent and Trademark Office. 123 Metabolite contended that LabCorp's
reliance upon the standard established in Parker v. Flook124 was
misplaced because that case had been supplanted by the Supreme
Court's subsequent holding in Diehr that a process employing a
natural phenomenon and resulting in a practical use falls within §
101.125
Metabolite further scoffed at LabCorp's prediction of dire
consequences for medical practice and research should the Court
uphold the validity of the patent.126 Metabolite maintained that it
neither claimed nor sought "a monopoly on the correlation between
total homocysteine and vitamin deficiencies."'127 Rather, Metabolite
argued that the patent merely claimed a "particular application of
that correlation, when used as a sequential step in a diagnostic
method."' 28 Metabolite insisted that the natural process of correlation
between homocysteine and vitamin deficiency was not at issue in the
claim, merely the means of making such a correlation.
129
As an example of a non-infringing use of the correlation in
claim 13, Metabolite offered a study wherein the authors
recommended prophylactic administration of folate and cobalamin in
order to reduce homocysteine levels and prevent disease in which no
levels of homocysteine were measured in any of the experimental
subjects. 130 Metabolite further argued that a failure by the Court to
support the validity of the '658 patent would undermine the validity of
121. Id.
122. Id. at 36-37. Metabolite states that "claim 13 does not 'disclose mere abstract
ideas, but a practical and potentially life-saving process."' Id. at 37 (quoting Arrhythmia
Research Tech., Inc. v. Corazonix Corp., 958 F.2d 1053, 1065-66 (Fed. Cir. 1992) (Rader, J.,
concurring)).
123. Id. at 37 ("The PTO defines 'concrete' as the opposite of 'unrepeatable or
unpredictable."').
124. 437 U.S. 584, 593-95 (1978).
125. Brief for Respondents, supra note 98, at 37 (citing Diamond v. Diehr, 450 U.S.
175, 188, 192 (1981)).
126. See id. at 38.
127. Id. at 39.
128. Id.
129. See id. at 39.
130. Id. at 41 (citing Joint Appendix at 107-08, Metabolite Labs., Inc. v. Lab. Corp. of
Am. Holdings, 370 F.3d 1354 (2005) (No. 04-607)).
PATENTLY WRONG
"hundreds or thousands of patents on medical diagnostic methods,
which frequently recite the sequential steps of assaying (or
determining) the amount of a particular substance [in] the body and
correlating the determined amount with a disease."
131
One example of such a threatened patent recited by Metabolite
was U.S. Patent No. 6,811,993, which claims a method for evaluating
the activity of an enzyme (protein kinase C) in vascular tissues.
132
Claim 1 of that patent requires a three-step diagnostic procedure in
which the level of protein kinase C is assayed, optionally compared to
a standard, and correlated with the determined level of a disease.
33
Thus, the use of a "marker" as an indicator of the presence or absence
of a disease is, according to Metabolite, a common feature of claims in
patented diagnostic methods.
134
Finally, Metabolite argued that the standards established by
the Court in Diamond v. Diehr provided a workable patent
jurisprudence and, furthermore, that it is within Congress's power to
alter patent law should Congress find it to be in the public interest to
do so. 135 Finally, Metabolite argued that the Federal Circuit, as the
"expert court" established by Congress, should be the first body to
consider policy issues.
136
III. WHY THE SUPREME COURT SHOULD HAVE INVALIDATED CLAIM 13
OF THE '658 PATENT
A. Misconstruction of the Term "Correlating" by the District and
Federal Circuit Courts
The district court, in its Markman hearing, properly
determined that the term "correlating" should be construed as it
would be understood by a person of ordinary skill in the art; that is "'a
person having a medical degree and experience in researching the
amino acid homocysteine and its relationship to diseases."' 3 7 It then
went on to define "correlating" as "relating total homocysteine levels to
131. Id. at 45.
132. See id. (citing U.S. Patent No. 6,811,993 col.7-8 (filed Dec. 21, 2001)).
133. Id. (citing '993 Patent col.7-8).
134. Id. ("Markers" are "proteins, enzymes, amino acids, [and] other substances that
change... in the presence of disease.").
135. See id. at 46-47.
136. Id. at 47.
137. Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1361 (Fed.
Cir. 2004) (quoting the jury instruction from the district court trial and noting that the
parties agreed on the level of ordinary skill in the art).
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cobalamin or folate deficiency, a deficiency in both, or a deficiency in
neither."'138 In other words, the district court and the Federal Circuit
construed "correlating" to mean determining the levels of total
homocysteine in a patient's body tissues and then inferring from those
levels whether a corresponding deficiency of folate and/or cobalamin
exists.139
Such a definition is a misconstruction of the term as it would
be understood by a biomedical researcher of ordinary skill in the art
(as defined by the courts). "Correlation" is a term of scientific art-a
precisely-defined statistical term for inferring a possible relationship
between two independent sets of measured variables. 140 Correlation
requires more than a strong association between two variables; the
variables must be related to appropriate time-order, and a possible
causal relationship must be the only explanation for the strong
association between the two variable sets. 141 Unlike the district
court's construction of the claim, in which correlation is understood to
be an inferential relationship between a single datum and a known
condition, correlation as understood by biomedical researchers
requires ascertaining the relationship between two sets of data, each of
multiple paired variables.
The calculation of the correlation coefficient between two sets
of paired data is thus an indicator of the reliability of the linear
association between any two paired variables and also an index of the
likelihood of cause and effect between dependent and independent
variables. 142 The essential point is that, in order for a researcher of
ordinary skill in the art to determine that a correlation exists between
variables (for example, total homocysteine levels in a body fluid and
138. Id. at 1363.
139. See id. According to the Federal Circuit, "[i]n essence, 'correlating' means to
relate the presence of an elevated total homocysteine level to either a cobalamin or folate
deficiency, or both (i.e., a mutual relationship), and also to relate the absence of an elevated
total homocysteine level to a deficiency in neither (i.e., a reciprocal relationship)." Id.
140. See P.V. RAO, STATISTICAL RESEARCH METHODS IN THE LIFE SCIENCES 442
(Alex Kugushev ed., 1998).
141. Id. For example, to establish a "significant positive correlation between [two
variables] X and Y, where X is the change in the subject's anxiety level (measured on a
numerical scale) and Y is the corresponding change in the subject's blood pressure," the
investigator must demonstrate that the anxiety was induced before the change in blood
pressure was noted and that, for this particular set of data, "only a change in anxiety level
can cause a change in blood pressure." Id.
142. See id. at 435-36. The correlation coefficient is established by letting "(xi, yi),
(x2, y2). ... [and] (Xn, yn) denote a random sample of n pairs of observed values of a pair of
continuous variables (X, Y)." Id. at 434. Next, the correlation coefficient is calculated as:
"rxy = Sxyl4SxSyy, where Sx = Z (xi - Y )2, Syy = Y (yi - 5;)2 and Sy = Y (xi- Y )(yi- 3i)." Id. at
396, 434.
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the level of cobalamin and/or folate), both variables need to be
observed (measured) multiple times, generating two sets of paired
variables. A correlation between the relative levels of homocysteine
and vitamins may then be determined by calculating the correlation
coefficient to determine whether a linear relationship between the two
exists, wherein the high levels of the former reliably indicate a causal
deficiency of the latter.
This is a far cry from the much more casual definition placed
upon the term "correlate" by the district court and affirmed by the
Federal Circuit. 143 "Correlate," as defined by those courts, describes
an inferential process by which the relative concentration of
homocysteine levels is used to predict whether or not there is a
vitamin deficiency. 144 This cannot be a correlation, as understood in a
scientific context, unless a corresponding measurement of the relative
concentrations of folate or cobalamin are made and the values
compared to the homocysteine level are applied. Thus, for a physician
to infringe by correlating she must measure both homocysteine and
vitamin levels in multiple patients and test those levels statistically to
determine if a correlation indeed exists.
It is true that the inventor of a patented device or method may
choose to define terms in a manner specific to the patent, but such
terms must be clearly defined in the specification or prosecution
history. 145 However, the '658 patent employs the term "correlate" in
its specification in a manner entirely consistent with its common
usage in the art.146 In the study described in Example 1, serum
cobalamin and folate levels were measured and correlated with a
number of contemporaneously measured hematological criteria,
including homocysteine and methylmalonic acid levels.1 47  The
example clearly demonstrates a usage of the term "correlate" in a
manner consistent with the scientific usage of the term.
The misconstruction of the term speaks to the very heart of the
case. Claim 13 of the '658 patent should be properly determined to be
143. See Metabolite Labs., Inc., 370 F.3d at 1363.
144. See supra text accompanying notes 48-56.
145. See Vitronics Corp. v. Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed. Cir. 1996).
The Vitronics court noted that:
rallthouah words in a claim are generally given their ordinarv and customary
meaning, a patentee may choose to be his own lexicographer and use terms in a
manner other than their ordinarv meaning, as long as the special definition of
the term is clearly stated in the patent specification or file history.
Id.
146. See U.S. Patent No. 4,940,658 col.10-12 (filed Nov. 20, 1986).
147. See '658 Patent col.10 1.38-43, col. 111.46-48.
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infringed only when a physician measures both homocysteine and
folate and/or cobalamin levels, and then correlates the two values. As
the American Clinical Laboratory Association pointed out in its brief
as amicus curiae:
The alleged infringement on the part of doctors is not correlating in its usual sense,
because the doctors are not establishing the relationship between homocysteine
and the B vitamins (each physician is not, for example, performing separate
controlled experiments on large numbers of patients) but rather applying that
relationship in specific instances as part of patient care.
148
Because the courts below misconstrued the term "correlate," in the
absence of an alterative definition supplied by the inventors, the
Supreme Court should have vacated the earlier decisions and
remanded the case to the district court with instructions to construe
the term within its proper meaning as understood by those of ordinary
skill in the art. A physician who measures homocysteine levels by a
(non-infringing) assay and uses the results to infer that the patient
suffers from cobalamin or folate deficiency is not performing any sort
of statistical correlation, and does not infringe. Nor did LabCorp
induce infringement by performing non-infringing assays or
publishing information concerning the relationship between
homocysteine levels and vitamin deficiencies because these activities
do not fall within the scientific definition of "correlating."
B. The Supreme Court Can Examine the Patentability of the Subject
Matter under 35 U.S.C. § 101
In its brief, Metabolite attempted to checkmate LabCorp's
argument that the '658 patent is invalid because it claims a basic
scientific fact in violation of 35 U.S.C. § 101.149 According to
Metabolite, because LabCorp failed to plead invalidity under § 101 in
the lower courts, it was barred from doing so in its argument before
the Supreme Court.' 50  Metabolite invoked both statutory and
148. Brief of the American Clinical Laboratory Ass'n as Amicus Curiae Supporting
Petitioner at 6, Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006)
(No. 04-607) (mem.), 2005 WL 3543098.
149. See Brief for Respondents, supra note 98, at 21. Section 101 states that
"[w]hoever invents or discovers any new and useful process, machine, manufacture, or
composition of matter, or any new and useful improvement thereof, may obtain a patent
thereof, subject to the conditions and requirements of this title." 35 U.S.C. § 101 (2000).
The statute has been regularly interpreted to forbid the patenting of laws of nature,
natural phenomena, and abstract ideas such as mathematical formulae. See, e.g., Diamond
v. Diehr, 450 U.S. 175, 185 (1981) ("Excluded from such patent protection are laws of
nature, natural phenomena, and abstract ideas.").
150. See Brief for Respondents, supra note 98, at 22.
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procedural authority in support of its argument.151 Metabolite argued
that having failed to plead invalidity under § 101, LabCorp had in
effect abandoned its right to raise it as an "affirmative defense" and
the Court was therefore precluded from considering it under the
Patent Act of 1952 and the Federal Rules of Civil Procedure.1 52
Metabolite went so far as to invoke the Seventh Amendment, arguing
that, because "no jury ha[d] found the factual predicates [necessary] to
a Section 101 defense," the Court could not find the '658 patent
invalid.1 53 Implicit in Metabolite's argument was the assumption that
without the facts having been tried before a jury, a § 101 "affirmative
defense" could not be pleaded before the Supreme Court.
Metabolite's argument, however, is unpersuasive. Failing to
mount an attack on the validity of the '658 patent on § 101 grounds in
the lower courts was undoubtedly poor legal strategy and a major
oversight by LabCorp. However, unlike defenses mounted on issues of
fact, which cannot be raised on appeal if they are not pled in the trial
court, the validity of a patent based on the patentability of the subject
matter under § 101 is a matter of law and may be reviewed sua sponte
by the Court. 154 In Slawson v. Grand Street Railroad Co., the
Supreme Court established that "the question whether [the] invention
is patentable or not, is always open to the consideration of the court,
whether the point is raised by the answer or not."1 55 The precedents,
though old, remain good law, although they have not been relied upon
often by courts.
More recently, however, the Federal Circuit itself has raised §
101 concerns sua sponte. In Titanium Metals Corp. of America v.
Banner, the Federal Circuit held that the issuance of a patent was
clearly erroneous based upon § 101 and reversed the decision of the
district court, holding a patent invalid.' 56 As Judge Garjasa of the
Federal Circuit recently pointed out in SmithKline Beecham Corp v.
Apotex, Corp, although the Slawson case is old, the policy behind the
decision remains vibrant.157 Judge Garjasa noted that, less than a
151. See supra text accompanying notes 98-111.
152. See Brief for Respondents, supra note 98, at 19-20.
153. Id. at 41 n.21 (citing Dimick v. Schiedt, 293 U.S. 474, 486-87 (1935)).
154. See SmithKline Beecham Corp. v. Apotex Corp., 403 F.3d 1331, 1352-54 (Fed.
Cir. 2005) (Gajarsa, J., concurring) (providing examples of courts independently raising §
101 concerns).
155. 107 U.S. 649, 652 (1883); see also Richards v. Chase Elevator Co., 158 U.S. 299,
301 (1895) ("We have repeatedly held that a patent may be declared invalid for want of
novelty, though no such defense be set up in the answer.").
156. 778 F.2d 775, 783 (Fed. Cir. 1985).
157. SmithKline Beecham Corp., 403 F.3d at 1353 (Gajarsa, J., concurring).
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decade after Slawson, the Supreme Court, in the context of a patent
interference, emphasized that: "[T]he parties to the present suit ...
have litigated merely the question of priority of invention, on the
assumption that the invention was patentable. But neither the
Circuit Court nor this court can overlook the question of
patentability."158 Judge Gajarsa further observed that the Supreme
Court has "recognized that there is a significant public policy interest
in removing invalid patents from the public arena." 159  In United
States v. Glaxo Group, Ltd., the Court cited numerous cases as
"sufficient authority" to support its statement that .'[iut is as
important to the public that competition should not be repressed by
worthless patents, as that the patentee of a really valuable invention
should be protected in his monopoly."'
160
Another policy consideration supporting the Supreme Court's
ability to review the subject matter eligibility of a patent sua sponte is
that in the United States, unlike in Europe, there is no right of third-
party opposition to the validity of a patent's subject matter.
161
Therefore, the Supreme Court is the ultimate protector of the public
from "bad patents" attempting to monopolize ineligible subject matter.
As such, the power of the Court to examine any patent for § 101
eligibility is an important power protecting society.
These arguments are reflected in Justice Breyer's dissent in
Metabolite. 62 Justice Breyer argued that the technical procedural
objection to hearing the case was too tenuous to stand, citing prior
Supreme Court precedent for the proposition that the failure to make
a § 101 argument in itself was an insufficient reason for denying
review.163 Moreover, Justice Breyer could see "no good practical
158. Id. (quoting Hill v. Wooster, 132 U.S. 693, 698 (1890)) (alteration in original).
159. Id. at 1354 (citing Cardinal Chem. Co. v. Morton Int'l, Inc., 508 U.S. 83, 100
(1993); Blonder-Tongue Labs., Inc. v. Univ. of Ill. Found., 402 U.S. 313 (1971); United
States v. Glaxo Group Ltd., 410 U.S. 52, 57-58 (1973)).
160. 410 U.S. 52, 57-58 (1973) (quoting Pope Mfg. Co. v. Gormully, 144 U.S. 224, 234
(1892)). The issue before the Court was whether the United States could set aside a patent
in the context of antitrust litigation. Id. at 57.
161. See Syntex (U.S.A.) Inc. v. U.S. Patent & Trademark Office, 882 F.2d 1570,
1574-75 (1989) (noting that, while statutory provisions grant third-parties the right to
request reexamination by the PTO, those provisions "do not provide for judicial review...
for any party other than the patent owner"). The grant of a European patent can be
opposed by a third-party within nine months of the date of grant. A successful opposition
can result in the complete revocation of the European patent in all of the designated states.
Convention on the Grant of European Patents arts. 99-102, Oct. 5, 1973, 13 I.L.M. 268,
294-95.
162. Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No.
04-607) (mem.) (Breyer, J., dissenting).
163. See id. at 2925-26 (citing United States v. Williams, 504 U.S. 36, 40 (1992)).
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reason" not to decide the case: the arguments had been fully briefed
and argued, and there were no gaps in the factual record or any
prejudice identified by either party in answering the question.
164
Thus, the Court had ample precedent and scope to review the
patentability of the subject matter of claim 13 of the '658 patent under
§ 101. Furthermore, neither statute nor the Federal Rules of Civil
Procedure barred it from doing so. It is likely that LabCorp did not
endear itself much to the Justices on the Court by raising the issue of
§ 101 at this stage of the case; however, to argue, as Metabolite did,
that LabCorp was barred from doing so ignored the Court's own latent
power to examine the patentability of subject matter at any time. The
public policy reasons alone support the contention that, if claim 13 is
indeed "invalid" under § 101, the public interest is well-served in
removing it from the public arena.
165
Metabolite further argued that the Court's own rules prevented
LabCorp from presenting the issue of the validity of claim 13's subject
matter. 166 Metabolite contended that the question of subject matter
patentability was not "fairly included in Question 3,"167 which was the
only question upon which the Court had granted certiorari. Question
3 asks:
Whether a method patent setting forth an indefinite, undescribed, and non-
enabling step directing a party simply to "correlate" test results can validly claim a
monopoly over a basic scientific relationship used in medical treatment such that
any doctor necessarily infringes the patent merely by thinking about the
relationship after looking at a test result.
168
Metabolite maintained that the language of Question 3 restricted the
Court to reviewing only the lower court's holding of validity on
grounds that claim 13 meets the written description and best mode
requirements of 35 U.S.C. § 112.169 But the plain language of the
question brought the validity of the subject matter itself into sharp
focus. In short, the real question before the Court was whether
patenting a test that requires a physician to simply correlate test
results can allow the inventor to obtain a monopoly over a basic
scientific fact. By centering the question squarely upon the "monopoly
164. Id. at 2926.
165. See SmithKline Beecham Corp. v. Apotex Corp., 403 F.3d 1331, 1354 (Fed. Cir.
2005) (Gajarsa, J., concurring) (citing 35 U.S.C. § 101).
166. See Brief for Respondents, supra note 98, at 25-26; supra text accompanying
notes 100-103.
167. Brief for Respondents, supra note 98, at 25.
168. Petition for Writ of Certiorari, supra note 74, at i.
169. See Brief for Respondents, supra note 98, at 25-26.
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over a scientific fact," the issue of subject matter patentability came
before the Court's consideration.
C. The '658 Patent is Invalid Under 35 U.S.C. § 101
Claim 13 of the '658 patent claims a method for using any
assay (including those claimed in the '658 patent, those in the prior
art, and, presumably, those not yet invented or developed) for total
homocysteine in body tissues to "correlate" elevated homocysteine
levels with folate or vitamin B12 (cobalamin) deficiencies.170 The
biochemical relationship between elevated levels of homocysteine and
vitamin deficiencies is a basic scientific principle, grounded in the
biochemistry of homeothermic ("warm-blooded") animals, including
humans. 171 Homocysteine levels were raised in humans suffering
from vitamin deficiencies long before the very existence of
homocysteine or folate and cobalamin were even imagined. Such basic
scientific relationships are "manifestations of nature" and are
expressly precluded from being patentable; 172 a biochemical reaction
occurring naturally in animals and resulting in the production of
methionine from 5-methyl tetrahydrofolate via the actions of
homocysteine and folate/cobalamin is no different in its essence than
is the relationship between energy, matter, and the speed of light in
E=mc2 . It is well-established that such natural phenomena may not
be patented under 35 U.S.C. § 101.173
However, it is equally well-established that a new invention
that employs a "manifestation of nature" is patentable under § 101.174
Those portions of the '658 patent that claim a novel technique for
determining total homocysteine measured from body tissues of a
warm-blooded animal 175 are perfectly valid insofar as they describe a
170. See U.S. Patent No. 4,940,658 col.6 11.1-4 (filed Nov. 20, 1986).
171. See SMITH ET AL., supra note 26, at 732.
172. See Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
173. See id. For example,
a new mineral discovered in the earth or a new plant found in the wild is not
patentable subiect matter. Likewise. Einstein could not patent his celebrated law
that E = mc2: nor could Newton have patented the law of aravitv. Such
discoveries are "manifestations of ... nature, free to all men and reserved
exclusively to none."
Id. (quoting Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 130 (1948) (alteration
in original)).
174. See, e.g., Diamond v. Diehr, 450 U.S. 175, 192 (1981) ("[Wlhen a claim
containing a mathematical formula implements or applies that formula in a structure or
process which ... is performing a function which patent laws were designed to protect ...
then the claim satisfies the requirements of § 101.").
175. See '658 Patent cols.41-44 (filed Nov. 20, 1986).
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technique that is useful, novel, and nonobvious when viewed in light
of the prior art.176 However, claim 13 of the '658 patent goes beyond
those limits and claims the use of all assays for homocysteine,
including those found in the prior art, those claimed in the patent, and
even those not yet developed, when used to predict or infer a folate or
cobalamin deficiency from increased homocysteine levels. 177 By so
claiming every possible assay for homocysteine, Metabolite attempts
to corner the market on the entire genus of homocysteine tests when
applied to the determination of a law of nature.
The problem with such a claim is that it attempts to include all
possible homocysteine tests, including those not yet anticipated by
those of ordinary skill in the art, such as the later-developed and non-
infringing Abbott Laboratories' assay.178 Such a claim to an entire
genus (i.e. all past, present, and future assays for homocysteine levels
in warm-blooded animals) by claiming one or two species is
impermissible.1 79 Metabolite may prevent competitors from infringing
upon the claims described with definiteness under the claims of its
patent, but it may not lay claim to all possible methods, including
those not yet invented or anticipated, of describing a phenomenon of
nature.
Metabolite's argument thus resembled a house of cards. Claim
13 of the '658 patent impermissibly claims an entire genus from a
limited number of species. But, even if such a claim was permissible,
the patent impermissibly claims a phenomenon of nature, inherent in
the biochemistry of living systems, and attempts to establish a
monopoly over any inference or conclusion arising from knowledge of
that inherent biochemical relationship.
Justice Breyer's dissent addressed this argument eloquently,
arguing that, no matter how narrowly one constructs the "phenomena
of nature" argument, claim 13 is invalid.18 0 According to Justice
Breyer, "[t]here can be little doubt that the correlation between
homocysteine and vitamin deficiency set forth in claim 13 is a 'natural
176. 35 U.S.C. §§ 101-03 (2000 & Supp. 2003-2004).
177. See supra text accompanying notes 48-56, 138-139.
178. Metabolite Labs., Inc. v. Lab. Corp. of Am. Holdings, 370 F.3d 1354, 1359 (Fed.
Cir. 2004); see also supra text accompanying notes 48-56, 138-139.
179. See Metabolite Labs., Inc., 370 F.3d at 1367 ("A prior art reference that
discloses a genus still does not inherently disclose all species within that broad category.");
accord Corning Glass Works v. Sumitomo Elec. U.S.A., Inc., 868 F.2d 1251, 1262 (Fed. Cir.
1989) ("[A] claim to a genus would inherently disclose all species. We find [this] argument
wholly meritless whether considered under [35 U.S.C. §] 102(b) or under 35 U.S.C. § 103.").
180. See Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921, 2926-
27 (2006) (No. 04-607) (mem.) (Breyer, J., dissenting).
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phenomenon."" 8'1 Claim 13, as Breyer noted, "is not a process for
transforming blood or any other matter.'18 2  Instead, claim 13's
process "instructs the user to (1) obtain test results and (2) think
about them.' 18 3 Moreover, claim 13 instructs the user to "use any test
at all."'18 4 No precedent cited by Metabolite suggests that such a claim
concerning natural phenomena might be patentable. 8 5  Despite
Metabolite's attempts to couch claim 13 in "the abstract patent
language of a 'process,"' it "cannot avoid the fact that the process is no
more than an instruction to read some numbers in light of medical
knowledge."'' s6 As such, according to Breyer, the "correlation is an
unpatentable 'natural phenomenon,"' and there is "nothing in claim 13
that adds anything more of significance.' ' 7
D. Sound Policy Reasons Militate Against the Validity of the '658
Patent
Numerous amicus briefs were filed with the Supreme Court on
behalf of LabCorp arguing that granting validity to a patent that
claims a basic scientific fact will stifle innovation and basic biomedical
research and will directly conflict with patient care. 88 These concerns
were also acknowledged by Justice Breyer in his dissent. 8 9 Despite




185. See id. (citing Gottschalk v. Benson, 409 U.S. 63, 71-73 (1972); Cochrane v.
Deener, 94 U.S. 780, 785 (1877)).
186. Id. at 2928.
187. Id.
188. See, e.g., Brief of AARP as Amicus Curiae Supporting Petitioner at 2, Lab. Corp.
of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-607) (mem.), 2005
WL 3597809; Brief of the American Clinical Laboratory Ass'n as Amicus Curiae Supporting
Petitioner, supra note 148, at 8-13; Brief for the American Medical Ass'n et al. as Amici
Curiae Supporting Petitioner at 23-26, Lab. Corp. of Am. Holdings v. Metabolite Labs.,
Inc., 126 S. Ct. 2921 (2006) (No. 04-607) (mem.), 2005 WL 3597812; Brief of Financial
Services Industry as Amici Curiae Supporting Reversal at 1, Lab. Corp. of Am. Holdings v.
Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-607) (mem.), 2005 WL 3543097; Brief
of People's Medical Society as Amicus Curiae Supporting Petitioner at 21-26, Lab. Corp. of
Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921 (2006) (No. 04-607) (mem.), 2005
WL 3597702.
189. See Metabolite Labs., Inc., 126 S. Ct. at 2928-29 (Breyer, J., dissenting)
(expressing concern that a failure to decide the case leaves restrictions in place that "may
inhibit doctors from using their best medical judgment; . . .may divert resources from the
medical task of health care to the legal task of searching patent files for similar simple
correlations; [and] may raise the cost of healthcare while inhibiting its effective delivery").
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Metabolite's assertions to the contrary, such policy concerns have real
merit and should have been addressed by the Court in an opinion.
One argument is that if an individual claiming a basic
scientific fact, such as a relationship between elevated homocysteine
levels and vitamin deficiency, is "permitted to patent any means of
testing for [that relationship,] then that patentee may 'shut the door'
to the development or use of such new tests, and discourage further
research and development." 190 Indeed, the Federal Circuit holding
arguably subjects laboratories to damages and penalties for inducing
infringement of a patent "simply by informing physicians, in an article
for continuing medical education, that high levels of an amino acid
signal a risk to patient health."191 Such a ruling undoubtedly inhibits
the dissemination of basic scientific facts essential to medical research
and education.1 92  In its amicus brief, the American Medical
Association (the A.M.A.) illustrated by way of example how
overreaching Metabolite's argument was.1 93 It noted that, under the
Federal Circuit's logic, if a researcher "discover[ed] a previously
unknown correlation between obesity and illness, . . . [he] could obtain
a patent on the process of stepping on a scale and thinking of that
illness."1 94  Any entities manufacturing scales or publishing
information (including in a medical textbook) concerning the
relationship between obesity and the illness would then be liable for
willfully inducing infringement.' 95 According to the A.M.A., "[s]uch a
result is unthinkable.' ' 96
Similarly, the A.M.A. argued that any physician who knows of
the relationship between elevated homocysteine levels and vitamin
deficiency would be practically unable to avoid infringing claim 13 of
the '658 patent.1 97  A physician or scientist who learns of the
relationship "cannot put that knowledge out of mind"; such knowledge
is "essential to the practice of medicine" and, once learned, cannot be
intentionally forgotten.1 98 In the practice of medicine, a physician is
"ethically obligated" to consider the results of diagnostic tests "in light,
190. Brief for the American Medical Ass'n et al. as Amici Curiae Supporting
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among other things, of current medical knowledge." 199 Scientific facts,
once known, must be considered and should not be constrained by the
claims of a patent to their consideration in diagnosis. 200 For this
reason, facts are not, and ought not to be, patentable.
Furthermore, if a patent can prevent dissemination of scientific
fact by making publishers liable for inducing infringement, it might
well be found to chill protected First Amendment speech.20 1 The
Supreme Court has previously held that "the state may not,
consistently with the spirit of the First Amendment, contract the
spectrum of available knowledge." 20 2 By enforcing as valid a patent
that claims basic scientific knowledge concerning a natural
phenomenon, the state is in fact contracting the spectrum of such
knowledge available to be freely used by medical practitioners and
investigators.
IV. CONCLUSION
In Laboratory Corp. of America Holdings v. Metabolite
Laboratories, Inc., the U.S. Supreme Court had the opportunity to
prevent the claiming of basic scientific knowledge as patently valid
subject matter. It is undeniable that LabCorp was not well-served by
the legal strategy it employed in the lower courts, and the Supreme
Court likely looked unfavorably upon LabCorp's raising the subject of
invalidity on § 101 grounds at such a late date in the proceedings.
Nevertheless, as Justice Breyer noted in his dissent, neither precedent
nor the question raised before the Court on certiorari precluded the
Court from examining the validity of the '658 patent on those
grounds. 203 Furthermore, it is self-evident that claim 13 of the '658
patent claims a phenomenon of nature in violation of 35 U.S.C. § 101.
Moreover, there is solid legal ground upon which to argue that both
the district court and the Federal Circuit erroneously construed the
term "correlating" as it would be understood by one of ordinary skill in
the art. Finally, there are compelling policy arguments militating in
favor of invalidating claim 13.
In a time when the increased liberality of American courts
concerning the patenting of genes and other biological material has
199. Id. at 26.
200. See id.
201. See Brief of People's Medical Society as Amicus Curiae Supporting Petitioner,
supra note 188, at 19-21.
202. Id. (quoting Griswold v. Conn., 381 U.S. 479, 482 (1965)).
203. Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 126 S. Ct. 2921, 2925-26
(2006) (No. 04-607) (mem.) (Breyer, J., dissenting).
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become a matter of widespread debate, the implied upholding of the
validity of the '658 patent, particularly claim 13, by the Supreme
Court represents a further and troubling erosion of the long-held bar
on the patenting of natural or scientific phenomena. Moreover, it
poses a significant threat to the modern practice of medicine and
physicians' ability to provide the best possible care to their patients.
If, by merely considering the relationship between a clinical indication
and the possibility of a disease, a physician is potentially infringing a
patent, then diagnosis becomes a thickly-strewn minefield of potential
patent liability. Such a threat, if vigorously pursued, is likely to exert
a chilling effect on the ability of physicians to best care for their
patients. Indeed, if the diagnosis of a disease by clinical indicators is
protectable, and if every textbook and diagnostic handbook's
description of biological relationships is patentable, then even basic
medical education and clinical training pose a risk of giving rise to
litigation.
Regrettably, the Supreme Court gave no reason for why it
dismissed Metabolite after the case had been thoroughly briefed and
argued. Given the potential consequences of letting the Federal
Circuit's decision stand, some explanation of why the Court dismissed
the case as having been improvidently granted a writ of certiorari
would be welcome. Better yet, the Court should have decided the case
correctly and delivered an opinion invalidating claim 13 of the '658
patent.
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